Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Immusoft logo — Cell therapy company dedicated to improving the lives of pat...

Immusoft

Cell therapy company dedicated to improving the lives of patients with rare diseases

Founded 2009 United States Seattle, United States 22 employees Grant Total: $49.27M Biotechnology, Health Care +2

General Information

Company Name Immusoft
Founded Year 2009
Location United States Seattle, United States
Founders / Decision Makers
Team member
Employees 22
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Grant
Business Model B2B, B2C, B2D
Revenue Model Licensing, Performance Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Immusoft. To contact Immusoft, visit immusoft.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Immusoft compare?

A PDF of Immusoft and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Immusoft soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Immusoft

Immusoft, a pioneering cell therapy company, is committed to revolutionizing treatments for patients suffering from rare diseases. Utilizing a cutting-edge technology platform known as Immune System Programming (ISP™), Immusoft modifies a patient's B cells to act as miniature drug factories, producing gene-encoded medicines designed to provide long-term therapeutic benefits. This technique offers a novel approach to sustained protein delivery, promising years of relief for patients.

Established in 2009 and headquartered in Seattle, WA, Immusoft operates within the Biotechnology, Health Care, Health and Wellness, and Life Sciences sectors. As of its last financial update, the company secured an $8.00M Grant investment from the California Institute for Regenerative Medicine on 27 January 2023. This infusion of capital underlines confidence in Immusoft's innovative mission to tackle rare diseases.

Business keywords: Cell Therapy, Rare Diseases, Therapeutic Proteins, Immune System Programming, B Cell Modification, Gene-Encoded Medicines, Miniature Drug Factories, Sustained Drug Delivery, Gene Editing, Biologics Production, Caltech Licensing, Immune System Reprogramming

Services & Products

B Cell Programming
Therapeutic Protein Development
Clinical Research and Development
Biologics Optimization

Target Customers

Patients with Rare Diseases Biopharmaceutical Companies Healthcare Providers Research and Development Organizations

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $8.00M 1
California Institute for Regenerative Medicine
27 Jan 2023
Grant $4.00M 1
California Institute for Regenerative Medicine
29 Nov 2021
Venture Round $4.50M 3
Breakout Ventures Ikarian Capital Mesa Verde Venture Partners
Breakout Ventures, Ikarian Capital +1
25 Sep 2020
Grant $467.00K 1
National Institutes of Health
25 Sep 2020
Series B $20.00M 7
Breakout Ventures Alexandria Venture Investments Bios Partners
Breakout Ventures, Alexandria Venture Investments +5
03 Jan 2019
Grant $3.50M 1
National Institute of General Medical Science
05 Sep 2018
Series B $3.00M 6
EQx Fund Invariantes Fund Technium Partners
EQx Fund, Invariantes Fund +4
05 Jan 2018
Series A $2.70M 3
Breakout Ventures Technium Partners
Breakout Ventures, Technium Partners +1
07 Nov 2016
Debt Financing $375.00K 1
Westcott LLC
Westcott LLC
18 Aug 2015
Series A $2.37M 2
Founders Fund Westcott LLC
Founders Fund, Westcott LLC
21 Aug 2014

View All 12 Funding Rounds

Immusoft Alternatives & Competitors

View All Alternatives
Immusoft vs
Affinia Therapeutics
Affinia Therapeutics United States

Building the next generation of gene therapies

Series C
34 employees
Biotechnology, Health Care
Immusoft vs
Orchard Therapeutics - U.S.
Orchard Therapeutics - U.S. United Kingdom

Dedicated to transforming the lives of patients with severe and other genetic diseases through innov...

Post-IPO Equity
238 employees
Biotechnology, Health Care
Immusoft vs
Edity Therapeutics
Edity Therapeutics Israel

Using human immune cells to deliver therapeutic proteins

Seed
22 employees
Biotechnology, Health and Wellness
Also compare with: Immusoft vs Outpace Bio Outpace Bio View all alternatives

FAQ About Immusoft

Cell therapy company dedicated to improving the lives of patients with rare diseases
Immusoft was founded in 2009.
Immusoft is headquartered in Seattle, United States.
Immusoft operates in Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on Cell Therapy, Rare Diseases, Therapeutic Proteins and Immune System Programming. Its customers include Patients with Rare Diseases, Biopharmaceutical Companies and Healthcare Providers.
Immusoft has a B2B, B2C and B2D business model. Its revenue comes from Licensing, Performance Based and Service Fee.
Immusoft has approximately 22 employees.
Immusoft has completed 12 funding rounds, raising a total of $49.27M. The latest funding stage is Grant.
Immusoft offers: B Cell Programming, Therapeutic Protein Development, Clinical Research and Development, Biologics Optimization.
Top alternatives and competitors to Immusoft include Affinia Therapeutics, Orchard Therapeutics - U.S., Edity Therapeutics , Eterna Therapeutics, Hopewell Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immusoft and Affinia Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Immusoft, https://bouncewatch.com/company/immusoft, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes